GlassScriptPhysician profile
Ryan Bowe
NPI 1356847636
$28,603.75
in general payments reported to CMS, 2019-2025
36 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,749 · 2022: $2,972 · 2023: $3,484 · 2024: $3,371 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $11K · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,200.00 |
| Food and Beverage | $10,570.76 |
| Education | $111.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14,764.57 | 2021-2025 | Zepbound, Emgality, Reyvow |
| Abbvie INC. | $3,015.07 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $1,632.46 | 2021-2025 | Ajovy, Austedo Xr |
| Amgen INC. | $1,342.17 | 2021-2024 | Aimovig, Krystexxa |
| Pfizer INC. | $1,052.72 | 2023-2025 | |
| Lundbeck LLC | $936.59 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $855.34 | 2022-2023 | Trudhesa |
| Currax Pharmaceuticals LLC | $683.35 | 2021-2025 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceutical Holding Company LTD. | $544.33 | 2022 | |
| Tonix Medicines, INC. | $509.29 | 2024-2025 | Zembrace Symtouch |
| Biohaven Pharmaceuticals, INC. | $311.09 | 2021 | |
| Ucb, INC. | $300.77 | 2023-2025 | Nayzilam, Briviact |
| Eisai INC. | $282.27 | 2024-2025 | |
| Novo Nordisk INC | $267.01 | 2023-2025 | Wegovy |
| Horizon Therapeutics Plc | $257.86 | 2023 | Krystexxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $254.87 | 2023-2025 | Ztlido, Elyxyb |
| Impel Pharmaceuticals LLC | $196.59 | 2024-2025 | Trudhesa |
| Upsher-Smith Laboratories LLC | $193.84 | 2021-2023 | |
| Sk Life Science, INC. | $193.22 | 2021-2023 | |
| Azurity Pharmaceuticals, INC. | $136.63 | 2023-2024 | Eprontia, Zonisade, Gliadel |
| Collegium Pharmaceutical, INC. | $119.23 | 2022 | |
| Novocure INC. | $110.02 | 2021-2023 | Optune |
| Axsome Therapeutics, INC. | $94.87 | 2025 | Symbravo |
| Averitas Pharma INC. | $79.18 | 2024-2025 | Qutenza |
| Ibsa Pharma INC. | $68.14 | 2024-2025 | Tirosint, Licart, Flector |
| Jazz Pharmaceuticals INC. | $62.11 | 2022 | |
| Arbor Pharmaceuticals, INC. | $60.27 | 2021 | |
| Merck Sharp & Dohme LLC | $57.92 | 2023-2024 | Welireg |
| Catalyst Pharmaceuticals, INC. | $56.95 | 2022-2023 | Firdapse |
| Supernus Pharmaceuticals, INC. | $45.55 | 2021-2022 | |
| Medline Industries LP | $37.29 | 2024 | Medline |
| Csl Behring | $27.72 | 2025 | Hizentra |
| Allergan, INC. | $22.12 | 2022 | |
| Ge Healthcare | $17.74 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $14.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$454,112.61 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.